Cortexyme, Inc. (NASDAQ:CRTX) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics that target microbial proteases implicated in chronic diseases. Since its founding, Cortexyme has focused on the connection between the oral pathogen Porphyromonas gingivalis and neurodegenerative disorders, particularly Alzheimer’s disease. By inhibiting the toxic proteases produced by P. gingivalis, the company aims to halt or reverse disease progression, offering a new approach to conditions that have historically lacked effective disease-modifying treatments.
The company’s lead product candidate, atuzaginstat (formerly COR388), is an orally administered small molecule that selectively inhibits gingipains, the proteases secreted by P. gingivalis. Atuzaginstat has advanced through clinical trials evaluating safety, target engagement and biomarkers of disease activity in mild to moderate Alzheimer’s disease. In addition to its Alzheimer’s program, Cortexyme is expanding its pipeline to address other indications where microbial proteases are believed to play a role, including diabetic retinopathy and Parkinson’s disease. The company’s research platform leverages proprietary screening technologies to identify and optimize inhibitors against disease-relevant proteases.
Headquartered in South San Francisco, Cortexyme operates research and development facilities in California and collaborates with leading academic institutions and clinical research organizations. The company’s clinical studies for Alzheimer’s disease are conducted across multiple sites in North America and Europe, reflecting its commitment to global patient enrollment and data collection. Through strategic partnerships and investigator-sponsored trials, Cortexyme continues to explore the broader applicability of its protease inhibitor platform in both neurologic and systemic diseases.
Cortexyme’s leadership team combines expertise in drug discovery, clinical development and corporate governance. Stephen S. Dominy, the company’s co-founder and chief executive officer, has a background in translational neuroscience and has overseen the advancement of atuzaginstat from concept to late-stage clinical testing. The management team includes seasoned professionals in regulatory affairs, manufacturing and business development, supported by a board of directors with extensive experience in biotechnology and life sciences. Since its inception, Cortexyme has maintained a strategic focus on translating scientific insights into potential therapies for patients with unmet medical needs.
AI Generated. May Contain Errors.
